title: Bacterial resistance in urinary tract infections in patients with diabetes matched with patients without diabetes.
abstract: BACKGROUND
  With bacterial resistances having increased, patients with diabetes who are at higher risk of urinary tract infection (UTI) need to be studied. The study aim was to compare bacterial resistances to ofloxacin, cefixim, co-trimoxazole, nitrofurantoin and fosfomycin in UTI between patients with and without diabetes.
  
  
  METHODS
  A cross-sectional study was conducted in ambulatory laboratories, including patients over 18 coming for urinalyses. Patients with diabetes were matched with two patients without diabetes based on risk factors for UTI using a propensity score.
  
  
  RESULTS
  Among 1119 patients with UTI, 124 patients with diabetes were matched with 246 patients without diabetes. In patients with diabetes, the bacteria identified were: Escherichia coli (71%), Klebsiella (6%), Staphylococcus (5%), Enterococcus (4%), Proteus (2%) and Pseudomonas (1%); these findings were similar to those found in patients without diabetes. Resistances to ofloxacin and cefixim regardless of the bacteria were increased in patients with diabetes after matching on age, sex and history of UTI (respectively: OR=2.09; p=0.04 and OR=3.67; p=0.05). Regarding E. coli resistance, there was no difference whatever the antibiotic.
  
  
  CONCLUSIONS
  The increased ofloxacin and cefixim resistance in patients with diabetes should be considered when prescribing probabilistic antibiotics, and could lead to changes in first-line treatments in UTI.
authors: Université Paris Descartes, Faculté de Médecine, Department of family medicine, 24, rue du Faubourg Saint-Jacques, 75014 Paris, France. Electronic address: malmartel.alexandre@gmail.com.
authors: Alexandre
authors: A
authors: Malmartel
authors: Université Paris Descartes, Faculté de Médecine, Department of family medicine, 24, rue du Faubourg Saint-Jacques, 75014 Paris, France. Electronic address: docghasa@aol.com.
authors: Christian
authors: C
authors: Ghasarossian
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D020682:Cefixime / Q000494:pharmacology; D003430:Cross-Sectional Studies; D048909:Diabetes Complications / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology* / Q000652:urine; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007709:Klebsiella / Q000187:drug effects / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000494:pharmacology; D057216:Propensity Score; D011511:Proteus / Q000187:drug effects / Q000302:isolation & purification; D011549:Pseudomonas / Q000187:drug effects / Q000302:isolation & purification; D012307:Risk Factors; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000652:urine
chemical_list: D000900:Anti-Bacterial Agents; D020682:Cefixime; D015242:Ofloxacin
keywords: Bacterial resistance; Diabetes; Urinary tract infection